Semapimod: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 31: | Line 31: | ||
| routes_of_administration = |
| routes_of_administration = |
||
}} |
}} |
||
Semapimod, formerly known as CNI-1493, was first developed to inhibit nitric oxide synthesis by inflammatory macrophages, via inhibition of the uptake of arginine which macrophages require for nitric oxide synthesis.<ref>{{cite pmid|8529104}}</ref> Subsequently it was found that suppression of nitric oxide synthesis occurred even at semapimod concentrations 10-fold less than required for inhibition of arginine uptake, suggesting that this molecule was a more general inhibitor of inflammatory responses.<ref>{{cite pmid|8642296}}</ref> |
Semapimod, formerly known as CNI-1493, was first developed to inhibit [[nitric oxide]] synthesis by inflammatory [[macrophages]], via inhibition of the uptake of [[arginine]] which macrophages require for nitric oxide synthesis.<ref>{{cite pmid|8529104}}</ref> Subsequently it was found that suppression of nitric oxide synthesis occurred even at semapimod concentrations 10-fold less than required for inhibition of arginine uptake, suggesting that this molecule was a more general inhibitor of [[inflammatory]] responses.<ref>{{cite pmid|8642296}}</ref> Further work revealed that semapimod suppressed the [[translation (genetics)|translation]] efficiency of [[tumor necrosis factor]] production.<ref>{{cite pmid|8632999}}</ref> Specifically, semapimod was found to be an inhibitor of [[p38 kinase|p38 MAP kinase]] activation.<ref>{{cite pmid|9205949}}</ref> |
||
{{reflist}} |
{{reflist}} |
||
Revision as of 17:02, 9 May 2009
 | This article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This article was last edited by Lanulos (talk | contribs) 15 years ago. (Update timer) |
 | |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| Chemical and physical data | |
| Formula | C34H56Cl4N18O2 |
| Molar mass | 890.73984 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Semapimod, formerly known as CNI-1493, was first developed to inhibit nitric oxide synthesis by inflammatory macrophages, via inhibition of the uptake of arginine which macrophages require for nitric oxide synthesis.[1] Subsequently it was found that suppression of nitric oxide synthesis occurred even at semapimod concentrations 10-fold less than required for inhibition of arginine uptake, suggesting that this molecule was a more general inhibitor of inflammatory responses.[2] Further work revealed that semapimod suppressed the translation efficiency of tumor necrosis factor production.[3] Specifically, semapimod was found to be an inhibitor of p38 MAP kinase activation.[4]
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8529104, please use {{cite journal}} with
|pmid=8529104instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8642296, please use {{cite journal}} with
|pmid=8642296instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8632999, please use {{cite journal}} with
|pmid=8632999instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9205949, please use {{cite journal}} with
|pmid=9205949instead.